Ide-Cel Shows Durable Response in R/R Multiple Myeloma: Larry D. Anderson, Jr, MD, PhD


The hematologist/oncologist from the Harold C. Simmons Comprehensive Cancer Center discussed the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.

This content originally appeared on our sister site, Targeted Oncology.

Targeted Oncology spoke with Larry D. Anderson, Jr, MD, PhD, hematologist/oncologist, Harold C. Simmons Comprehensive Cancer Center and associate professor, Division of Hematology/Oncology, Department of Internal Medicine, UT Southwestern Medical Center, about the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.

Long-term data for idecabtagene vicleucel (ide-cel, bb2121) demonstrated deep and durable remissions in a majority of patients on the trial, according to Anderson. Patients with relapsed/refractory multiple myeloma on this trial had a median of 6 prior lines of therapy. With a median 24.8-month follow-up, the median overall survival on trial was 24.8 months also. For the 128 patients, there was a 73% overall response rate, and the median progression-free survival (PFS) was 8.6 months. Those who received the target dose of 450 million chimeric antigen receptor T cells had a median PFS of 12.2 months.

Anderson says another notable topic was the FDA label for ide-cel requires patients to have 4 prior lines of therapy while the trial only required 3 prior lines of therapy. One of the study analyses looked at efficacy for patients who received 3 prior lines versus 4 or more. There was not a significant difference in outcomes for these 2 groups.

Related Videos
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
© 2024 MJH Life Sciences

All rights reserved.